RxDoctor Payments Data

Paxton Longwell, MD

Neurology · Corpus Christi, TXNPI 1518074095

Payments from drug & device makers

$1,691in general payments, 2019–2025

Across 96 payments — averaging $17.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$497
  • AbbVie$304
  • GE HealthCare$115
  • AstraZeneca$100
  • Biogen$90
  • Supernus Pharmaceuticals, Inc.$84
  • plus $500 from 17 others

What the payments were for

  • Food & beverage$1,691100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,691 in reported general payments places this provider in the 40th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$132,691
Medicare patients
498
Services billed
1,216

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EnspryngSatralizumab-Mwge14$248,640
Avonex Pen (4 Pack)Interferon Beta-1a15$122,748
AubagioTeriflunomide12$114,706
RebifInterferon Beta-1a/Albumin11$112,990
IngrezzaValbenazine Tosylate13$105,254
Dimethyl Fumarate46$69,536
GlatopaGlatiramer Acetate22$52,495
Glatiramer Acetate20$47,737
BriviactBrivaracetam11$15,895
Carbidopa-Levodopa ErCarbidopa/Levodopa223$10,906
Rufinamide13$9,783
Oxcarbazepine78$7,711
Levetiracetam180$6,799
Venlafaxine Hcl ErVenlafaxine Hcl170$3,918
Carbamazepine ErCarbamazepine20$3,915

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
EMD Serono, Inc.Rebif$58$112,99011 claims
UCB, Inc.Briviact$53$15,89511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,246 neurology providers in Texas.

Other neurology in Corpus Christi

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →